Verwijs Marinus 4
4 · Aerovate Therapeutics, Inc. · Filed Mar 20, 2024
Insider Transaction Report
Form 4
Verwijs Marinus
Senior Vice President, CMC
Transactions
- Exercise/Conversion
Common Stock
2024-03-19$14.59/sh+5,300$77,327→ 5,300 total - Sale
Common Stock
2024-03-19$25.68/sh−2,536$65,119→ 2,764 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-19−5,300→ 84,700 totalExercise: $14.59Exp: 2032-03-20→ Common Stock (5,300 underlying) - Sale
Common Stock
2024-03-19$26.46/sh−2,764$73,124→ 0 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.255 to $26.125, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.30 to $26.71, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.